DB

David Bonita

Director at Ikena Oncology

David Bonita is a General Partner at OrbiMed Advisors. David currently serves on the boards of directors of Acutus Medical Inc. (Nasdaq: AFIB), IMARA Inc. (Nasdaq: IMRA), Prelude Therapeutics, Inc. (Nasdaq: PRLD), Repare Therapeutics Inc. (Nasdaq: RPTX), and Tricida, Inc. (Nasdaq: TCDA), as well as several private companies. David also previously served on the boards of directors of Clementia Pharmaceuticals Inc., Loxo Oncology, Inc., SI-BONE, Inc., and ViewRay Inc. Prior to OrbiMed, David worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has published scientificarticles in peer-reviewed journals based on signal transduction research performed at Harvard Medical School. He received his B.A. in biology from Harvard University and his joint M.D./M.B.A. from Columbia University.


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Ikena Oncology

Ikena is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer.


Industries

Employees

11-50

Links